CA-THEOREMONE
25.1.2022 00:39:08 CET | Business Wire | Press release
Theorem, LLC, innovation and engineering partner to the Global 1000, today announced that it has rebranded to TheoremOne® following an acquisition of Formula Partners , and launch of its near-shore, pureplay software engineering service, Lemma . The new name positions TheoremOne as the foundation of a family of brands designed to help enterprises build better, more innovative business platforms at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220124005847/en/
“Our new name positions TheoremOne as the foundation of a family of brands, all inspired by our hypothesis driven model for innovation. Each brand is designed to address the specific needs of our clients at different moments in the lifecycle of enterprise innovation,” said Brady Brim-DeForest, CEO of TheoremOne.
Its newest acquisition, Formula Partners, helps companies create new models for organizational design, continuous improvement, and visionary leadership. Formula Partner’s approach revolves around a modular innovation process called the New Enterprise™, a proprietary model for modern consulting at the nexus of technology and organizational transformation. Formula Partners will become a new independent line of business and will operate under the “Formula Partners” brand.
“We are approaching management consulting from 14 years of implementing technology solutions — giving us a deep understanding of the true benefits (and costs) of making strategic recommendations. We’ve built trust with IT and business leaders through hands-on work, and we’re excited to build even broader strategic relationships through Formula Partners,” said Will Jessup, Head of Services Delivery at TheoremOne.
TheoremOne has also launched a new engineering service called Lemma. Lemma offers pureplay software engineering teams staffed exclusively by nearshore engineering talent. Lemma shares a common engineering DNA with TheoremOne but is designed to deliver engineering capacity as a modular service offering that can be deployed to scale existing teams and initiatives for enterprise and growth stage clients.
“Lemma fills a gap in our offerings that the market has illuminated over the last few years,” said Alex Finnemore, TheoremOne’s Head of Revenue. “It’s a compelling option for clients that have already determined the right way to solve a business problem and need a dedicated technology partner, but want to provide their own product, design, and leadership talent.”
Lemma and Formula Partners will join existing divisions Proof (staff augmentation) and Halmos Ventures (innovation incubation) in rounding out TheoremOne’s end-to-end services stack.
As part of the name change, TheoremOne has released a new company logo and launched a new website at www.theoremone.co .
About TheoremOne®
TheoremOne is an innovation and engineering firm that builds custom software for companies making bold bets to stay ahead. Through research, lean design, and agile delivery, TheoremOne makes great user experiences accessible to the enterprise. Founded in 2007, TheoremOne’s global cross-functional product development teams drive technology, process, and cultural transformation. To learn more about how TheoremOne enables ambitious leaders to build better software visit www.theoremone.co or follow @TheoremOne
About Formula Partners
Formula Partners is a different kind of management consulting firm — it targets the intersection of technology and organizational transformation, unlocking models for continuous improvement, and enabling visionary leadership within the enterprise. Founded in 2015, Formula Partners is based in Los Angeles. Read more at: www.formula.partners .
About Lemma
Lemma offers pureplay software engineering teams designed to deliver high-quality results at-scale. Clients come to Lemma when they need an injection of fully-managed and modular engineering talent. Learn more about Lemma at: www.thinklemma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005847/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 14:01:00 CEST | Press release
DCX introduces groundbreaking new safety standard protecting critical AI infrastructure by monitoring and keeping the entire coolant loop Continuous monitoring of eight coolant parameters and automatic dosing keep hall-scale liquid-cooling loops in specification between service visits Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 14:00:00 CEST | Press release
Company’s Third Largest Shareholder Expects Update on Increased Transparency, Strategic Review of Xerox Financial Services Business Unit, and Continued DeleveragingSTARTEEPO Chairman František Bostl to Address Xerox Investment at Skytop Conference in London STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executin
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release
Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release
New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release
More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom